Centessa Pharmaceuticals (NASDAQ:CNTA) Rating Lowered to Hold at Lifesci Capital

Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by equities research analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

Other research analysts have also issued reports about the stock. Leerink Partners lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their target price for the stock from $36.00 to $40.00 in a research report on Wednesday. Wolfe Research lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday. Needham & Company LLC cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Oppenheimer raised their price objective on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Finally, B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Hold” and an average price target of $40.00.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $39.69 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals has a one year low of $9.60 and a one year high of $40.26. The firm has a market capitalization of $5.80 billion, a P/E ratio of -21.69 and a beta of 1.25. The company’s fifty day moving average is $26.93 and its two-hundred day moving average is $25.45.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Monday, April 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). Analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Activity

In other news, insider Iqbal J. Hussain sold 38,951 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the transaction, the insider directly owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This trade represents a 40.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Karen M. Anderson sold 41,076 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the transaction, the insider owned 62,085 shares of the company’s stock, valued at $1,870,000.20. This represents a 39.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 349,073 shares of company stock worth $9,429,412 over the last ninety days. 7.09% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at $80,000. T. Rowe Price Investment Management Inc. raised its stake in Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares during the last quarter. Coastal Bridge Advisors LLC lifted its holdings in Centessa Pharmaceuticals by 7.1% in the 4th quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock valued at $351,000 after purchasing an additional 931 shares in the last quarter. XTX Topco Ltd purchased a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $1,978,000. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $8,710,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Key Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Lilly acquisition reported — Multiple outlets report Eli Lilly will acquire Centessa in a deal worth up to $7.8B; press coverage notes shareholders would receive roughly $38 in cash plus contingent value rights tied to potential upside, which sets a clear takeover premium/floor under the stock. LLY to Buy Centessa — Zacks
• Positive Sentiment: Large call buying — Reports show unusually high volume of call-option purchases, a bullish signal from derivatives traders that may reflect takeover-related arbitrage or speculative upside interest. Investors Purchase Calls — American Banking News
• Neutral Sentiment: Guggenheim reaffirmed “neutral” — Guggenheim left its rating unchanged, signaling no strong analyst upgrade in response to the takeover buzz. Guggenheim Reaffirms — TickerReport
• Neutral Sentiment: Leerink moved to “hold” but raised price target to $40 — A mixed note: downgrading the rating but nudging the target slightly above current market levels, reflecting uncertainty about deal dynamics or timing. Leerink Downgrade / PT — Benzinga
• Negative Sentiment: Multiple analyst downgrades — Several firms (B. Riley, Lifesci Capital, Wolfe Research, Needham, Stephens and others) cut ratings to hold from stronger stances, pressuring sentiment despite the takeover reports. Analyst Downgrades — Zacks Wolfe Research — American Banking News Needham — American Banking News
• Negative Sentiment: Shareholder investigations and class-action alerts — Two law firms announced probes into the proposed sale process and price adequacy, creating legal/transaction risk that can weigh on the stock and complicate closing. Monteverde & Associates — PR Newswire KSF Investigation — BusinessWire
• Negative Sentiment: Earnings miss — Centessa reported Q (EPS -$0.48) that missed consensus (~ -$0.38), an operational disappointment that adds near-term pressure independent of M&A news. Earnings Release — MarketBeat
• Negative Sentiment: Heavy put buying — Separately, unusual volume in put options (10,659 puts, a large jump vs. average) shows some participants betting on downside or using puts for hedging around the deal. (No direct link provided in feed.)

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.